New Israeli Production Site for NurOwn Certified for Quality
BrainStorm Cell Therapeutics announced that a new cleanroom facility for manufacturing NurOwn, its experimental cell-based therapy for amyotrophic…
Articles by Marta Figueiredo, PhD
Sperogenix Acquires Rights in China to Develop ABSK021
A subsidiary of Sperogenix Therapeutics has acquired exclusive rights to develop and commercialize ABSK021, an investigational oral therapy for …
Enrollment in Phase 3 Masitinib Trial Expected to Soon Resume in France
AB Science’s proposed measures to ensure patient safety in clinical trials of its experimental oral therapy masitinib were…
Clearing of Stress Granules, Linked to Cell Damage in ALS, Detailed
Ubiquitination — the cell’s process of tagging proteins, often to degrade unwanted ones — is essential for the disassembly of stress…
Tofersen Early Access Program Now Open to SOD1-ALS Patients
The first part of Biogen’s early access program for tofersen is now open to patients with the most rapidly…
Exservan, Riluzole Oral Film for ALS, Now Available in US
Exservan, the first oral film formulation of riluzole for treating amyotrophic lateral sclerosis (ALS), has been launched in the…
ALS Association Wants More Commitment From the FDA
In a response letter to The ALS Association, the U.S. Food and Drug Administration (FDA) has recognized the unmet therapeutic…
New Cellular Model Used to Study FUS Gene Mutations
Mutations in the FUS gene, a common cause of amyotrophic lateral sclerosis (ALS), impair the regeneration and growth of motor neuron extensions…
Most Caregivers Did Not Get Respite During Pandemic, UK Survey Says
Most unpaid caregivers in the U.K. have not had any breaks from their caregiving role during the COVID-19 pandemic,…
Amylyx Seeks Approval in Canada of Lead Candidate AMX0035
Amylyx Pharmaceuticals is seeking approval, in Canada, of its lead candidate AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). This regulatory…